Molecular image-guided therapy has been demonstrated to be effective in improving diagnosis, prognosis, planning, and monitoring of personalized medication. Molecular imaging modalities include positron emission tomography (PET), single-photon emission-computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), ultrasound (US), and optical imaging (Ramen, quantum dots, and bioluminescence). Among clinical molecular imaging modalities, radionuclide imaging technique is the most sensitive one which could provide target-specific information as well as function, pathway activities, and cell migration in the intact organism. For instance, the radiotracer could noninvasively assess diseases treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. New leads on the development of personalized theranostic (image and treat) agents would allow more accuracy in the selection of patients who may respond to treatment.

This special issue will provide a platform of efficacy of personalized medication from molecular imaging technology which will have high impact on drug discovery, delivery, and development. It will become a series of special issues that focused on molecular imaging and personalized therapy. The special issue will be of interest to not only translational research scientists but also supportive staff, such as molecular biologists, imaging scientists, pharmaceutical developers, physicists, fellows, and staffs. Scientists are invited to submit papers.

Potential topics include, but are not limited to:

• Image-guided theranostic approach of diseases
• Advances in bioimaging applications in preclinical drug discovery
• PET/CT and SPECT/CT in disease management
• Radiation dosimetric determination for radiotheranostic agents
• Imaging technology in drug development
• Validation of imaging agents on new molecular targets
• Personalized drug development from molecular imaging
• Nonradioactive molecular imaging probes